LLY$1,017.78
$1,020.45
Chart
Performance
Key Stats
AI LLY Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyEli Lilly and Company exhibits strong fundamental performance and positive thematic alignment, though its current valuation is high and technical indicators suggest a neutral to cautious short-term outlook. Suitable for growth-oriented investors with a long-term horizon.
Thematic
Eli Lilly is well-positioned to benefit from significant secular trends in healthcare, particularly in diabetes management, obesity treatment, and oncology innovation.
Fundamental
Eli Lilly demonstrates robust revenue growth, improving profitability, and a solid financial position, though the P/E ratio is high, reflecting strong market expectations.
Technical
The stock is in a strong uptrend, but recent price action shows mixed signals with indicators suggesting potential overbought conditions on shorter timeframes, warranting a neutral stance for short-term trading.
| Factor | Score |
|---|---|
| Diabetes and Obesity Treatment | 95 |
| Oncology Innovation | 88 |
| Alzheimer's Research | 80 |
| Regulatory Environment (Pharma) | 70 |
| Healthcare Spending Trends | 85 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 85 |
| Growth | 90 |
| Balance Sheet Health | 65 |
| Cash Flow | 80 |
| Dividend Yield | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 70 |
| Volume Confirmation | 75 |
| Support & Resistance | 70 |
| Short-Term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Earnings Growth
Quarterly earnings per share (EPS) estimates have shown consistent upward revisions. For instance, Q2 2025 estimate increased from $3.02 to $3.34, reflecting positive analyst sentiment and potentially stronger-than-expected future performance. The company has also exceeded earnings expectations in multiple prior quarters (e.g., Q3 2024 +50.92% surprise).
Attractive Valuation Metrics relative to Growth
While the TTM P/E ratio is 88.8, the projected P/E for 2024 is 65.2. When considering the company's growth prospects, the Price/Sales ratio of 15.3 for 2024 is notable, but the strong net income growth (23.5% net margin in 2024) suggests underlying profitability. Further analysis of a PEG ratio (if provided) would be beneficial, but current trends suggest potential value if growth is sustained.
Bearish Points (7)
High Valuation Multiples
The Price-to-Earnings (P/E) ratio on a trailing twelve-month (TTM) basis is 88.8, and the forward P/E for 2024 is 65.2. These multiples are significantly higher than the broader market, suggesting that the company's growth expectations are already priced in, potentially leading to a downside risk if growth falters.
Slowing Revenue Growth
While revenue for 2024 is projected at $45.04 billion, an increase from $34.12 billion in 2023, the quarterly revenue growth shows some volatility. For example, Q3 2024 revenue was $11.43 billion, a decrease from Q2 2024's $13.53 billion, and the net margin dipped to 8.5% in Q3 2024, indicating potential headwinds or cyclical factors impacting top-line performance and profitability conversion.
Calendar
August 2025
7
Next Earnings Date
H: $5.92
A: $5.58
L: $5.27
H: 14.99B
A: 14.66B
L: 14.30B
August 2025
15
Ex-Dividend Date
September 2025
10
Next Dividend Date
Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Seasonals
Price Target
952.27 USD
The 39 analysts offering 1 year price forecasts for LLY have a max estimate of 1190.00 and a min estimate of 650.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct and intense competitor in the rapidly growing diabetes and obesity markets, with GLP-1/GIP agonists like Ozempic and Wegovy directly competing with LLY's Mounjaro/Zepbound and Trulicity.
Weight: 95
Emerging direct competitor in the obesity and metabolic disorders space, developing VK2735, a dual GLP-1/GIP receptor agonist with promising clinical trial data, posing a future challenge to LLY's market leadership.
Weight: 90
Large-cap pharmaceutical peer with a broad and diversified pipeline, including metabolic (oral GLP-1 programs), oncology, and neuroscience, ensuring competition across multiple key LLY therapeutic areas.
Weight: 88
Global pharmaceutical company with strong market positions and R&D focus in oncology, cardiovascular, renal, and metabolism (including diabetes), creating significant competitive overlap with LLY.